BUY Conviction4/5 Analysis quality72/100 Price target255 now
The YouTuber is adding Biogen to his portfolio due to its valuation and healthcare's resistance to inflation. He notes its leadership in neurology R&D, a strong drug pipeline with 10 programs in Phase 3 or approved, and a solid balance sheet with significant free cash flow. The stock trades at a low 2.7 times price-to-sales, well below its five-year average and competitors.
“Biogen is a specialty drug maker focused mostly in neurology which has helped to create that leadership position in research and development in that space.”